ABK Biomedical Inc. (ABK) is pleased to announce a new multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®). MURR is the pre-eminent global leader in research reactors, with extensive experience supplying medical isotopes and irradiation services for medical devices. MURR is a key partner for ABK to establish seamless manufacturing, supply, and distribution to critical cancer centers globally.
MURR will be the primary irradiation partner for ABK’s radio-embolization products currently under development. MURR’s unparalleled reputation for quality control and reliable irradiation services will complement ABK in the research and development of EYE90TM yttrium 90 microspheres for the treatment of liver tumors.
Information about MURR: http://www.murr.missouri.edu/
MURR’s 10MW reactor operates 52 weeks/year for research and to serve patients